Literature DB >> 1475248

Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome.

J M Van Lith1, J J Pratt, J R Beekhuis, A Mantingh.   

Abstract

We measured immunoreactive inhibin in the maternal serum of 80 pregnancies with a chromosomally normal fetus and ten Down's syndrome pregnancies in the second trimester. The inhibin level in all Down's syndrome pregnancies was above the normal median; the multiple of the normal median (MoM) was 1.9. We found a statistically significant difference between the levels of inhibin in unaffected and affected pregnancies (Kolmogorov-Smirnov test: p < 0.002). Using an arbitrarily chosen cut-off of 2.4 MoM, 40 per cent of Down's syndrome and 5 per cent of the normal pregnancies were found. We conclude that immunoreactive inhibin may be useful as a marker for fetal Down's syndrome.

Mesh:

Substances:

Year:  1992        PMID: 1475248     DOI: 10.1002/pd.1970121005

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  4 in total

Review 1.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 2.  A historical and practical review of first trimester aneuploidy screening.

Authors:  Melissa L Russo; Karin J Blakemore
Journal:  Semin Fetal Neonatal Med       Date:  2013-12-14       Impact factor: 3.926

Review 3.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Comparison of different blood collection, sample matrix, and immunoassay methods in a prenatal screening setting.

Authors:  Jeroen L A Pennings; Jacqueline E Siljee; Sandra Imholz; Sylwia Kuc; Annemieke de Vries; Peter C J I Schielen; Wendy Rodenburg
Journal:  Dis Markers       Date:  2014-07-15       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.